2 most recent filings and news items mentioning CADL. Updated every 60 seconds.
LeadershipJul 17, 2026Negative
Cadrenal Therapeutics entered into a separation agreement with CMO James Ferguson III following his voluntary resignation for July 2026. This leadership change may impact the biotech firm's clinical development strategies.
View filing at SEC.gov →
LeadershipJun 16, 2026Neutral
Candel Therapeutics has entered into an employment agreement with Charles Schoch to serve as Chief Financial Officer effective June 12, 2026, with a base salary of $468,600 and target bonus of 40%. The appointment reflects the company's continued organizational development and fi
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.